Francoise Pierard
Vertex Pharmaceuticals
29 Papers
523 Citations
Francoise Pierard is an academic researcher from Vertex Pharmaceuticals. The author has contributed to research in topics: Kinase & Chemistry. The author has an hindex of 11, co-authored 29 publications.
Chat about Author
Papers
Patent
Azaindoles useful as inhibitors of JAK and other protein kinases
Francesco G. Salituro,Luc J. Farmer,Randy S. Bethiel,Edmund Harrington,Jeremy Green,John Court,Jon H. Come,Lauffer David J,Alex Aronov,Hayley Binch,Dean Boyall,Jean-Damien Charrier,Simon Everitt,Damien Fraysse,Michael Mortimore,Francoise Pierard,Daniel Robinson,Jian Wang,Joanne Pinder,Tiansheng Wang,Albert C. Pierce +20 more
- 30 Mar 2005
TL;DR: In this article, the authors present an invention related to inhibitors of protein kinases and provide pharmaceutical compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various disorders.
203
Patent
Compounds useful as inhibitors of atr kinase
Ahmad Nadia,Dean Boyall,Jean-Damien Charrier,Christopher John Davis,Davis Rebecca,Steven Durrant,Gorka Etxebarria I Jardi,Damien Fraysse,Juan-Miguel Jimenez,David Kay,Ronald Marcellus Alphonsus Knegtel,Donald Middleton,Michael O'donnell,Maninder Panesar,Francoise Pierard,Joanne Pinder,David Shaw,Pierre-Henri Storck,John Studley,Heather Twin +19 more
- 09 Nov 2012
TL;DR: In this paper, pyrrolopyrazines are used as inhibitors of ATR protein kinase, and they have a formula I wherein the variables are as defined herein, and the compounds of this invention have formula I.
131
The discovery of the potent aurora inhibitor MK-0457 (VX-680).
David Bebbington,Hayley Binch,Jean-Damien Charrier,Simon Everitt,Damien Fraysse,Golec Julian M C,David Kay,Ronald Knegtel,Chau Mak,Francesca Mazzei,Andrew Miller,Michael Mortimore,Michael O'donnell,Sanjay Patel,Francoise Pierard,Joanne Pinder,John Pollard,Sharn Ramaya,Daniel Robinson,Alistair Rutherford,John Studley,James Westcott +21 more
TL;DR: MK-0457 (VX-680) has been assessed in Phase II clinical trials in patients with treatment-refractory chronic myelogenous leukemia (CML) or Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ALL) containing the T315I mutation.
104
Design and optimization of selective protein kinase C θ (PKCθ) inhibitors for the treatment of autoimmune diseases.
Juan-Miguel Jimenez,Dean Boyall,Guy Brenchley,Philip N. Collier,Christopher John Davis,Damien Fraysse,Shazia Keily,Jaclyn Henderson,Andrew Miller,Francoise Pierard,Luca Settimo,Heather Twin,Claire M. Bolton,Adam P. Curnock,Peter Chiu,Adam Tanner,Stephen Clinton Young +16 more
TL;DR: Development of potent and selective PKCθ inhibitors, which show exceptional potency in cells and in vivo are described, which are expected to block autoimmune T cell responses without compromising antiviral immunity.
44
Patent
Azaindoles useful as inhibitors of protein kinases
Francoise Pierard,Juan-Miguel Jimenez,Ronald Kengtel,Guy Brenchley,Michael Mortimore,Francesca Mazzei +5 more
- 29 Jun 2005
TL;DR: In this paper, the pyrrolo ''2, 3-b! pyridine compounds useful as inhibitors of protein kinases are described and processes for preparing the compounds of the invention are provided.
43